Congress did not intend courts to conduct de novo review in private-party challenges to FDA rulemaking under the Dietary Supplement Health and Education Act and, therefore, the Act's de novo provision does not apply to plaintiff's challenge to the FDA's ruling that supplements containing ephedrine alkaloids (EDS) are adulterated under the Act's unreasonable-risk standard.
February 20, 2006 at 12:00 AM
1 minute read
Presented by BigVoodoo
New Jersey Law Journal honors lawyers leaving a mark on the legal community in New Jersey with their dedication to the profession.
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
ABOUT THIS RECRUITMENTOur attorneys face some of the most challenging, cutting-edge legal issues in the environmental field. As such, we ar...
Hofstra University enrolls over 6,000 undergraduate students and nearly 4,000 graduate students in 13 schools, which feature a variety of de...
McCarter & English, LLP is actively seeking a patent associate, patent agent, or technical specialist for its Intellectual Property Prac...
